LUNGevity Foundation Board of Directors

Alexander Stern, Chairman
Alexander Stern has served as Chief Operating Officer of Lazard Ltd since November 2008, and has been the Chief Executive Officer of Financial Advisory since April 2015. He has served as a Managing Director since January 2002 and as the Firm’s Global Head of Strategy since February 2006. Alex initially joined Lazard in 1994. As a Managing Director in Lazard’s Financial Advisory Group, he has worked on a broad array of assignments as a member of the Technology, Media and Telecommunications Group for such clients as IBM, Nextel, MCI, 360networks, Rural Cellular, Asia Global Crossing, SBC Communications, Cap Gemini, and Lotus.

Tom Galli, Treasurer
Galli founded Ingenium Cubed, LLC, a patent holding company. He holds three patents, is a published author, earned an MBA, and is a graduate of the Defense Systems Management College, the Defense Contract Audit Agency Institute, and the Armed Forces Staff College. Tom is a lung cancer survivor and a long-term LUNGevity LifeLine mentor. His career in the United States Army and the corporate world spans 45 years and includes a diverse background in civil engineering; tank-automotive system design, development and manufacturing; contracting; program management; and productivity and business process re-engineering consulting.

Peter Babej
Peter Babej is Global Head of Financial Institutions at Citigroup / Global Banking. Previously, Peter served as Global Co-Head of Financial Institutions at Citigroup/ Global Banking, as Co-Head of Financial Institutions – Americas at Deutsche Bank, and as a Managing Director at Lazard. Over the course of his career, Peter has advised many leading companies across the financial and public sectors worldwide with respect to both mergers and acquisitions and financing. Peter holds a BA from the Woodrow Wilson School of Princeton University as well as a JD and PhD from Harvard University.

Patrick Chen
Patrick Chen is the CEO of JD Capital USA. JD Capital is China’s largest private equity firm, and one of Patrick’s goals is to introduce LUNGevity to China. Patrick was formerly a senior executive at Industrial and Commercial Bank of China (ICBC), overseeing the bank’s global M&A activities. He has also worked for Shanghai International Securities, co-heading its international division. Patrick has master’s degrees from Indiana University and the Graduate School of People’s Bank of China. Patrick lost his mother to lung cancer.

Lynne Doughtie
Lynne Doughtie, Chairman and Chief Executive Officer of KPMG LLP, one of the world’s leading professional services firms, recently lost her mother to lung cancer and is passionate about wanting to make a difference in changing outcomes for all those affected by the disease. Lynne is a Governing Board member for the Center for Audit Quality and a member of The Committee of 200. She also serves as a board member for both NAF and the Partnership for New York City. Lynne has received numerous recognitions including being named one of: Fortune’s Most Powerful Women in Business, Accounting Today magazine’s Top 100 Most Influential People, and the National Association of Corporate Directors’
100 most influential people in the boardroom. Lynne also was named the 2015 “Woman of Achievement” by the National Association for Female Executives.

Andrea E. Ferris  
Andrea Ferris, President and CEO of LUNGevity Foundation, became deeply committed to finding a way to increase survivorship of lung cancer after losing her mother, Patricia Stern, to the disease. Along with her siblings and father, she co-founded Protect Your Lungs, an organization dedicated to research into the early detection of lung cancer, and served as Executive Director until its merger with LUNGevity Foundation in 2010. Prior to that she held a number of management positions at Decision Lens, Johnson & Johnson, and Coopers & Lybrand. Andrea holds an MBA from University of Pennsylvania’s Wharton School of Business with concentrations in finance and Latin American studies and a BS in Economics with concentrations in accounting, decision sciences, and finance.

William “BJ” Jones  
William “BJ” Jones is Chief Commercial Officer, Migraine and Common Diseases, at Biohaven Pharmaceuticals. His extensive commercial leadership experience at pioneering companies in the healthcare industry provides strategic insight and guidance to the Foundation in its work of changing outcomes for people with lung cancer.  
BJ brings a unique global healthcare perspective with his experience in mass market product launches. His work successfully building and leading diverse teams committed to addressing unmet patient needs will assist LUNGevity in continuing to identify and address unmet patient needs in the lung cancer community. BJ is a seasoned pharmaceutical executive with two decades of commercial and neuroscience expertise in large pharmaceutical companies and small biotech firms. BJ has held leadership roles of increasing responsibility at Takeda Pharmaceuticals, AstraZeneca, Bristol-Myers Squibb, Boehringer Ingelheim and NitroMed.

He has significant experience in mass market product launches and has successfully built and led diverse commercial teams committed to addressing unmet patient needs across various therapeutic areas, including neuroscience, cardio-metabolic, respiratory, GI, and infectious disease.

Prior to joining the pharmaceutical industry, BJ served in the U.S. Air Force and earned the rank of Major. He provided threat assessments to NATO leadership as an Engineering Analyst in the Foreign Technology division and led cutting-edge research in the Artificial Intelligence in Training program as a Function Chief in the AF Human Systems Division.

He holds a BS in Human Factors Engineering from the U.S. Air Force Academy, an MS in Industrial Engineering from Texas A&M University and an MBA from Stanford Graduate School of Business.

Jennifer Kashatus  
Jennifer Kashatus is a partner at DLA Piper LLP. She routinely advises companies in all industry sectors on privacy and cybersecurity issues. In particular, Jennifer assists companies in developing comprehensive global and domestic privacy and data security programs, guiding companies in navigating the myriad state, federal, and international privacy regulations. She also devotes a significant portion of her practice to incident response and preparation, having advised numerous companies on the implementation of an incident response program and coached companies through evaluating and responding to a threatened or actual security incident. Further, Jennifer routinely advises clients on
privacy and data security matters in the context of corporate transactions, working with clients to identify potential risks in an acquisition, whether buy or sell side. Jennifer’s work with state, federal, and international regulations is invaluable as LUNGevity continues its policy work to improve regulations and legislation impacting lung cancer patients.

Michael Marquis
Michael was appointed President of Vogue, a Johnson & Johnson Company, in 2016, and tasked with completing a seamless merger into J&J while plotting a path for Vogue’s growth. As a valued member of the North American Leadership Team at J&J, he continues to assume the business leadership for media planning and relations in the United States. He is also the executive sponsor for Happy Healthy Skillman, GenNext, the Veterans’ Leadership Council and the Diversity Marketing Leadership Team on behalf of the NALT. In 2014, Michael took on the challenge of turning around some declining business units at J&J. By focusing on core priorities and establishing a culture of health and learning, he was able to grow market shares of key product lines. Prior to that, Michael was responsible for the Global Oral Care Franchise at J&J, where headed up global strategy, marketing, innovation and business development into emerging markets. Mr. Marquis graduated from Bucknell University with a bachelor’s degree in Accounting.

Andre Owens
Andre’s legal practice, WilmerHale, focuses on securities trading and markets activities. He counsels broker-dealers, securities exchanges, investment advisers, and other clients on a variety of regulatory issues. Andre also provides advice with respect to acquisitions of securities broker-dealers and investment advisers. In the past, Andre served as a member of the Counseling and Regulatory Policy Group of the US Securities and Exchange Commission’s Office of General Counsel, where he provided advice and recommendations on various proposals presented for Commission action. He has also advised on policy issues as Counsel to SEC Commissioner Steven M. H. Wallman. Andre graduated from Providence College with a bachelor’s degree and holds a JD degree from Harvard Law School.

Michael Parisi
Michael has over 25 years of diverse healthcare industry experience with an intense focus on biotechnology and oncology. Currently he is the CEO of Guidemark Health, a diversified healthcare communications agency with a focus on oncology and rare diseases. Michael spent 17 years within the Ogilvy Healthcare organization, where he worked across all aspects of the oncology marketplace, creating long-standing partnerships with many biopharma companies and academic centers on the cutting edge of cancer research. He is a critical thinker, problem solver, and someone who thrives in new emerging approaches to solving the world’s biggest healthcare challenges. Named to the PharmaVOICE 100 Most Inspiring Healthcare Leaders in 2016 for his leadership and innovation in cancer and rare diseases, Michael is a recognized leader and cancer advocate. He currently serves as the President of the Board of Trustees of CancerCare, a partner of LUNGevity. Additionally, since 2012 he has served on the board of the NCCN Foundation, an organization that represents 28 of the world’s leading cancer centers. Michael holds a BA degree in psychology, which is where he became a hospice counselor, focused specifically on dealing with people suffering the end stage of a cancer diagnosis. He also holds an MBA in corporate finance.

Charles Rudin, MD, PhD
Dr. Charles Rudin is Chairman of LUNGevity’s Scientific Advisory Board and Chief of the Thoracic Oncology Service at Memorial Sloan Kettering Cancer Center. Dr. Rudin directs a broad research program of therapeutic research with the ultimate goal of improving the outcomes for patients with
lung cancer. His research includes laboratory-based investigations to identify and test novel treatment approaches to lung cancer, early-phase clinical trials to bring these ideas to the clinic, and later-phase studies to establish the efficacy of these new approaches. He also co-chairs the Eastern Cooperative Oncology Group Thoracic Committee, and is a member of the National Cancer Institute Thoracic Malignancies Steering Committee.

**Andrew Stern**

Andrew Stern has spent his entire career focused on early-stage company development, financing, and operations. At present, Andy is a Founder and Managing Partner at Five Points Partners, LLC, a New York-based business catalyst focused on building and operating a portfolio of companies in a variety of industries, including finance, technology, and multi-unit franchise concepts. Prior to joining FPP, Andy founded AMT Partners, an investment group focused on personal private equity investments. Previously, Andy was a Managing Director and Entrepreneur-In-Residence of idealab!, where he managed portfolio company development, which included idea vetting, strategic planning, and technical development.

**Paul G. Stern**

Paul Stern co-founded Protect Your Lungs with his children after his wife of 43 years, Patricia, died of lung cancer. Paul has been a leader in the business and non-profit community for more than four decades. He is the former Presiding Director of Dow Chemical Company and served as chair of the Governance Committee and as a member of the Audit and Executive Committees. He was also a Director of Whirlpool Corporation, where he chaired the Human Resources Committee and was a member of the Governance Committee of the Board. Paul is the chairman of the National Symphony Orchestra and is involved with many other philanthropic boards.

**Nichelle Stigger**

Nichelle Stigger is a lung cancer survivor-advocate whose cancer journey began in 2016 when she was diagnosed with a rare form of lung cancer, mucinous adenocarcinoma, found in only 1% of cancer patients. After two surgeries, including the removal of her left lobe and lymph nodes, she has been cancer-free since 2017. Nichelle has made it her fight to educate, facilitate, engage, and organize those in powerful positions to bring about change in the pursuit of equity for all.

Nichelle is an educator in Oak Park, IL, and, in addition to her passion for equality in cancer care, is an advocate for equality in education. She believes that knowledge can be a place of enlightenment, and she teaches her kids to practice leading with love in all interactions. Nichelle lives in Oak Park, IL, with her young son Parker and husband Aaron.

**Robert Winn, MD**

Robert Winn, MD is the director of Virginia Commonwealth University Massey Cancer Center. He brings years of experience in lung health and specifically lung cancer along with a passion for health equity and diversity that will help the Foundation grow strategically in ways that will have maximum impact on all who are affected by lung cancer.

Dr. Winn is the only African American to be appointed as director of a National Cancer Institute designated cancer center. As director of VCU Massey Cancer Center, Dr. Winn oversees a facility that provides outstanding cancer care, conducts groundbreaking research to discover new treatments for cancer, and offers high-quality education, training, and community outreach programs. Dr. Winn’s experience and expertise in these areas will help the Board to strategically guide the Foundation to shape our future programs and areas of engagement.
Dr. Winn is a long-standing advocate for health equity in lung cancer; he advocates for the expansion of access to high-quality, LDCT screening among underserved high-risk populations, integration of evidenced based tobacco treatment into screening programs, and inclusion of diverse populations into clinical and translational research. He has, throughout his career, modeled the growing and impactful behavior of cancer centers to tailor interventions to the needs of vulnerable populations by maintaining an ongoing relationship with community partners. He believes that the knowledge and trust gained by maintaining an ongoing relationship with community partners affords academic institutions the opportunity to tailor interventions to the needs of a vulnerable community and thereby increase the sustainability of efforts that influence patient outcomes.

Dr Winn’s notable research contributions include evidence of the need to redefine risk-based guidelines to improve the beneficial results in LDCT screening in African Americans that goes beyond focusing only on age and smoking status criteria.

**LUNGevity Foundation Scientific Advisory Board**

**Charles M. Rudin, MD, PhD, Chairman of LUNGevity’s Scientific Advisory Board**
*Memorial Sloan Kettering Cancer Center*
*Professor and Chief, Thoracic Oncology Service*

Dr. Rudin directs a broad research program of therapeutic research with the ultimate goal of improving the outcome for patients with lung cancer. His research includes laboratory-based investigations to identify and test novel treatment approaches to lung cancer, early-phase clinical trials to bring these ideas to the clinic, and later-phase studies to establish the efficacy of these new approaches. He is interested in small cell and non-small cell lung cancers. Some of the strategies his group has explored both in the laboratory and in the clinic include turning back on genes silenced in cancer, re-activating cancer cell death pathways, and treating lung cancer with a cancer-specific virus. Dr. Rudin also co-chairs the Eastern Cooperative Oncology Group Thoracic Committee, and is a member of the National Cancer Institute Thoracic Malignancies Steering Committee.

**Scott J. Antonia, MD, PhD**
*Duke Cancer Institute:*
*Director, Center for Cancer Immunotherapy*
*Duke University School of Medicine:*
*Instructor, Department of Medicine*

Dr. Antonia is the director of the DCI Center for Cancer Immunotherapy, a DCI Strategic Plan priority that aims to enhance the institute’s ability to develop and test novel immunotherapeutic approaches. In addition to his leadership role, he serves as an instructor at the Duke University School of Medicine.

After completing his medical oncology training and post-doctoral fellowship in the Flavell Lab at the Yale University School of Medicine, he joined H. Lee Moffitt Cancer Center in 1994. There, he served as chairman of the Department of Thoracic Oncology where he had oversight of a multidisciplinary clinic that saw 1,400 new lung cancer patients each year. He also built an active lung cancer clinical research program that resulted in 225 patients accrued to therapeutic clinical trials each year; half of which were investigator initiated trials (IITs), the majority being immunotherapy-focused. While at Moffitt Cancer Center Antonia was recognized as Physician of the Year (2005), Mentor of the Year (2008), and Researcher of the Year (2018).
Antonia is recognized as a global leader in the development of immunotherapy for lung cancer. He served as the global principal investigator for the practice-changing Pacific study, which established, as the new global standard of care, anti-PDL1 as consolidative therapy after combined chemo-radiation therapy for locally advanced non-small cell lung cancer. He was also the lead investigator of trials that established the clinical activity of immunotherapy for small cell lung cancer, resulting in the inclusion of this modality in the NCCN guidelines.

Antonia served for 10 years on the Administrative Core of the U54-funded academic partnership between the Ponce School of Medicine in Puerto Rico and Moffitt Cancer Center. He is currently the principal investigator of another multi-project, multi-institution grant funded by the Stand Up to Cancer organization (Tumor infiltrating lymphocyte adoptive T cell therapy for NSCLC). He is also the PI on an R01, and a recently awarded U01 from the NCI.

For 25 years at Moffitt Cancer Center, Antonia directed a translational research program that’s overall goal is to develop immunotherapeutic strategies for the treatment of cancer patients; using tumor vaccines or adoptive T cell therapies in combination with immunomodulatory strategies designed to thwart the immunosuppressive mechanisms used by tumors to evade T cell mediated rejection. He has extensive experience in conducting early-phase, first-in-man clinical trials testing therapeutic tumor vaccines and immunomodulatory antibodies. The latter includes anti-CTLA.4 (tremelimumab), an activating anti-CD40 antibody, and anti-PD1/PD-L1.

Philip D. Bonomi, MD
Rush University Medical Center
Alice Pirie Wirtz Professor of Medicine
Division of Hematology, Oncology and Cell Therapy
Dr. Bonomi has been involved in lung cancer research for almost three decades. He is a member of the International Association for the Study of Lung Cancer and has served as the Chairman of the Thoracic Committee for the Eastern Cooperative Oncology Group. His primary area of interest is within the field of thoracic and cardiothoracic oncology, with his specialties being in lung cancer and mesothelioma. The majority of Dr. Bonomi’s research interest is in the field of lung cancer treatment and detection. His most recent research has centered on the study of new chemotherapeutic agents for multi-modality therapies in the treatment of small-cell lung cancer. Dr. Bonomi has authored or co-authored more than 150 journal articles, primarily in the field of small cell lung cancer detection and survival-rate improvements.

Julie R. Brahmer, MD, MSc, FASCO
John Hopkins Kimmel Cancer Center
Bloomberg-Kimmel Institute for Cancer Immunotherapy
Director, Thoracic Oncology Program
Professor of Oncology
Dr. Brahmer is an international leader in the field of immunotherapy for patients with lung cancer. She is the author of more than 90 scholarly articles and has spoken on immunology at events nationwide. She was named director of the Thoracic Oncology Program at the Kimmel Center at Johns Hopkins University in January 2015. Dr. Brahmer is best known for her research related to the phase I trial of the PD-1 inhibitor nivolumab, an immunotherapy drug that has shown remarkable promise for lung cancer patients. She serves on the board of several national foundations.
Lauren Averett Byers, MD  
The University of Texas MD Anderson Cancer Center  
Associate Professor, Department of Thoracic/Head and Neck Medical Oncology, Div. of Cancer Medicine
Dr. Byers is an associate professor of Thoracic/Head and Neck Medical Oncology at The University of Texas MD Anderson Cancer Center. She has a bachelor’s in molecular biology from Princeton University and a master’s in cancer biology, with a specialization in patient-based research, from The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences. She also serves on the faculty of MD Anderson UTHealth Graduate School.

Dr. Byers earned her medical degree from Baylor College of Medicine. Following her internal medicine residency at Johns Hopkins School of Medicine, she returned to her home state of Texas for oncology fellowship training at MD Anderson. In 2010, Dr. Byers joined the faculty at MD Anderson. Using proteomic, gene expression, and genomic profiling assays, she has identified several promising molecular targets for treating lung cancer. These include the identification of poly ADP-ribose polymerase 1 (PARP1) and other genes involved in repairing DNA damage as novel therapeutic targets for small cell lung cancer (SCLC).

A world-class clinical and translational investigator, she currently leads several clinical trials testing PARP inhibitors and novel immunotherapy approaches for patients with recurrent SCLC.

Dr. Byers is the recipient of numerous awards and accolades and was a member of the inaugural group of LUNGevity Career Development awardees. Most recently, she was the recipient of an Andrew Sabin Family Fellowship to support her work in using novel CAR-T therapy for SCLC and the recipient of the President's Recognition for Research Excellence from MD Anderson. She is also an active member of the NCI's Thoracic Malignancy Steering Committee and the NCI's Progress in Small Cell Lung Cancer Working Group.

Dr. Byers is grateful for the critical support she received from LUNGevity early in her career, which helped her to establish her laboratory research program and has led to numerous discoveries being translated from the lab into clinical trials.

David P. Carbone, MD, PhD  
The Ohio State University  
Wexner Medical Center  
Comprehensive Cancer Center  
Professor, Division of Medical Oncology  
Barbara J. Bonner Chair in Lung Cancer Research  
Director of the Thoracic Oncology Center  
President, International Association for the Study of Lung Cancer (IASLC)
Dr. Carbone's research interests, grant support, and publications have been focused on lung cancer, specifically on proteomic and expression array signature development, lung cancer genetics, cancer immunotherapy, tumor-associated immunosuppression mechanisms, and gene therapy. Recent research directions include development of molecular biomarkers to guide patient management and
therapy, and molecular profiling of lung cancers and preneoplasias to guide the development of novel therapeutics, especially the use of mass spectrometry-based proteomics. He has over 200 peer-reviewed publications, books, and review articles, has served on several NCI grant review panels, and has had continuous NCI funding since early in his career. He has served on organizing committees for both ASCO and AACR and the Board of Scientific Counselors for the NCI, and is currently Chair of the Lung Biology subcommittee for the Eastern Cooperative Oncology Group and President-Elect of the International Association for the Study of Lung Cancer (IASLC).

Suzanne E. Dahlberg, PhD
Boston Children’s Hospital
Institutional Centers for Clinical and Translational Research
Assistant Director of Clinical Trial Biostatistics and Data Management
Suzanne Dahlberg is the Assistant Director of Clinical Trial Biostatistics and Data Management for the Institutional Centers for Clinical and Translational Research at Boston Children’s Hospital as well as a statistician collaborating with the hospital’s Divisions of Adolescent/Young Adult Medicine and Pulmonary Medicine. She has nearly 15 years of experience working in research, having previously worked in pediatric and thoracic oncology at Dana-Farber Cancer Institute and the ECOG-ACRIN Cancer Research Group. She holds a doctorate in Biostatistics from Harvard University, and her primary research focuses on the design, conduct, analysis and reporting of observational studies, pre-clinical experiments and phase I-IV clinical and translational trials. She is also interested in the design of expansion cohorts and the statistical challenges that arise from competing risks, masked-cause failure time data, and missing data.

Jessica S. Donington, MD, MScR
University of Chicago Medicine
Professor of Surgery
Chief, Section of Thoracic Surgery
Dr. Donington is Professor and Chief of the Section of General Thoracic Surgery at University of Chicago Medicine. Her clinical and interests focus on the early diagnosis and treatment of non-small cell lung cancer. Areas of expertise include the use of multimodality therapy for thoracic malignancies, treatment options for high risk patients with early stage lung cancer and lung cancer in women. She is the surgical chair for the thoracic oncology section of NRG Oncology Group. She is the immediate past president of the Women in Thoracic Surgery and the New York Society for Thoracic Surgery.

Steven M. Dubinett, MD
David Geffen School of Medicine at UCLA
Chief, Division of Pulmonary and Critical Care Medicine
Senior Associate Dean for Translational Research
Associate Vice Chancellor for Research
Director, Clinical and Translational Science Institute (CTSI)
Dr. Dubinett has extensive experience in translational investigation, academic administration, mentorship, and peer review. Building on original discoveries relevant to inflammation in the pathogenesis of lung cancer, he has developed a translational research program which now utilizes these laboratory-based discoveries in the translational research and clinical environment. His studies focus on the microenvironment, inflammation, and epithelial mesenchymal transition (EMT) in the pathogenesis of lung cancer. He serves as the Chair of the Research Evaluation Panel for biospecimen utilization for the American College of Radiology Imaging Network / National Lung Screening Trial (ACRIN / NLST). He also serves on the NCI Thoracic Malignancy Steering Committee as a Translational
Science Representative. Dr. Dubinett has trained more than 30 graduate students, post-doctoral fellows, and junior faculty, nearly all of whom have continued in academic careers.

**Patrick Forde, MD (MB, BCh)**  
*Johns Hopkins University Sidney Kimmel Comprehensive Cancer Center*  
*Associate Professor of Oncology*  
*Director of the Thoracic Cancer Clinical Research Program*  
Dr. Forde has led the development of a clinical-translational research program focused on the immunoncology of upper aerodigestive malignancies. Dr. Forde’s research examines the role of immunotherapy for earlier-stage lung cancer, and his work has led to the development of several ongoing phase III trials.

**Edward W. Gabrielson, MD**  
*Johns Hopkins University School of Medicine*  
*Professor of Pathology and Oncology*  
Dr. Gabrielson specializes in molecular pathology, with particular emphasis on the pathology of lung, breast, and esophageal cancers. His research emphasizes aspects that have potential clinical significance. Current areas of emphasis include molecular classification of cancers, genetic instability in cancer, and functional changes in cancers related to cell-cell interactions and cellular metabolism. Dr. Gabrielson serves as co-director of the graduate program in pathology. He has authored or co-authored numerous peer-reviewed publications.

**Edward B. Garon, MD**  
*Jonsson Comprehensive Cancer Center at UCLA:*  
*Director of the Thoracic Oncology Program*  
*David Geffen School of Medicine at UCLA:*  
*Associate Professor of Medicine*  
After growing up in Minneapolis, Dr. Garon earned a bachelor’s degree in biology at the Massachusetts Institute of Technology. His MD degree is from Washington University in St. Louis. He performed his internship and residency at the University of Chicago. After a chief residency at Cook County Hospital in Chicago, Dr Garon was a fellow in hematology and oncology at UCLA. He has remained at UCLA ever since and is currently an Associate Professor of Medicine in the Division of Hematology-Oncology at the David Geffen School of Medicine at UCLA. He also received a Master's degree in clinical investigation from UCLA.

Dr Garon has been the principal investigator of peer-reviewed grants from various funding organizations, including the National Cancer Institute. His focus is on clinical research and biomarker development. He has served as the principal investigator on national and international phase I, II, and III clinical trials, including trials that have led to the approval of multiple drugs, among them the non-small cell lung cancer drugs ramucirumab (Cyramza®) and the immunotherapy pembrolizumab (Keytruda®), along with a companion diagnostic.

**John V. Heymach, MD, PhD**  
*The University of Texas MD Anderson Cancer Center*  
*Professor and Chairman, Department of Thoracic/Head and Neck Medical Oncology, Division of Cancer Medicine*  
Dr. Heymach’s research focuses on investigating mechanisms of therapeutic resistance, understanding the regulation of angiogenesis in lung cancer, and developing biomarkers for selecting patients most
likely to benefit from targeted agents. Dr. Heymach has led a number of phase I/II clinical trials in non-small cell lung cancer and currently serves as the principal investigator on the BATTLE-frontline trial using novel combinations of targeted agents as frontline therapy for non-small cell lung cancer patients. His work has been extensively published in prominent peer-reviewed journals.

**Robert L. Keith, MD**  
*University of Colorado, Denver:*  
*Professor of Medicine and Cancer Biology*  
*Rocky Mountain Regional VAMC:*  
*Associate Chief of Staff-Research*  
Dr. Keith's research interests focus on the early detection and prevention of lung cancer. Specifically, his team is examining prostaglandin manipulation and PPAR gamma agonists in pre-clinical models of non-small cell lung cancer, including genetically modified mice. An NCI-sponsored human trial is nearing completion and he recently initiated an immunoprevention trial in high risk subjects. His team's chemoprevention trials include performing bronchoscopy to detect pre-malignant central airway lesions, and they are better characterizing these lesions to better determine which will progress to invasive lung cancer. This involves characterizing the epithelial cells, the lesional microenvironment, and biomarker discovery/validation.

**Benjamin P. Levy, MD**  
*Johns Hopkins School of Medicine:*  
*Associate Professor*  
*Johns Hopkins Sidney Kimmel Cancer Center. Washington, DC:*  
*Clinical Director*  
Dr. Benjamin Levy is associate professor at the Johns Hopkins School of Medicine and clinical director of the Sidney Kimmel Cancer Center, Johns Hopkins Medicine at Sibley Hospital in Washington, DC. Prior to his Hopkins appointment, Dr Levy was medical director of Thoracic Oncology Program for Mount Sinai Health Systems in New York City and associate director of the Cancer Clinical Trials Office (CCTO). Dr. Levy is a physician-scientist who is currently leading immunotherapy trials evaluating checkpoint point inhibitors with novel combination strategies, as well as targeted therapy trials. Dr. Levy has played an integral role on several American Society of Clinical Oncology (ASCO) committees and currently serves as associate editor for the ASCO University Committee as well as editor-in-chief for the ASCO Self-Evaluation Program (ASCO-SEP®). He recently completed two terms on the editorial board for the *Journal of Clinical Oncology (JCO)* and currently serves as senior associate editor for *Clinical Lung Cancer*. He is an ad hoc reviewer for *The Oncologist, Oncotarget, and Clinical Cancer Research (CCR)*. He was recently selected as one of only 15 oncologists in the country to join the prestigious ASCO Leadership Development Program, whose mission is to identify and develop future leaders of ASCO. It addition to his ASCO commitments, Dr. Levy serves on the ALLIANCE Respiratory Committee, the IASLC Staging Committee, and the IASLC Career Development & Fellowship Committee.
Christine M. Lovly, MD, PhD
Vanderbilt University Medical Center
Vanderbilt-Ingram Cancer Center
Associate Professor of Medicine, Division of Hematology-Oncology
Ingram Associate Professor of Cancer Research
Co-Leader, Translational Research and Interventional Oncology Program
Dr. Lovly is associate professor of medicine at the Vanderbilt University Medical Center and Vanderbilt Ingram Cancer Center as well as co-leader of the Translational Research and Interventional Oncology Program at Vanderbilt-Ingram Cancer Center. Dr. Lovly, a former LUNGevity Career Development Awardee, is a physician-scientist who splits her time between clinical care and laboratory research. Her clinical practice focuses primarily on the care of patients with lung cancer. Her laboratory research focuses on understanding and developing improved therapeutic strategies for specific clinically relevant molecular subsets of lung cancer. She is also co-editor-in-chief for the website www.mycancergenome.org, a Vanderbilt-initiated freely available website that aims to provide healthcare practitioners, patients, and advocates with up-to-date information on genetically-informed cancer medicine. Dr. Lovly received a BA in chemistry from Johns Hopkins University followed by MD and PhD degrees as part of the Medical Scientist Training Program at Washington University in St. Louis, MO. She then completed internal medicine residency and medical oncology subspecialty training at Vanderbilt University. During her final year of fellowship, she was the Jim and Carol O’Hare Chief Fellow. She started on faculty at Vanderbilt in July 2013.

Pierre P. Massion, MD
Vanderbilt-Ingram Cancer Center
Cornelius Vanderbilt Chair in Medicine
Professor of Medicine and Cancer Biology
Director, Thoracic Program
Dr. Massion is committed to pursuing innovative strategies to deepen the understanding of lung cancer development and progression. His laboratory applies novel genomic and proteomic technologies to biological specimens to address questions related to the identification and validation of molecular determinants of disease diagnosis, progression, prognosis, and intermediate endpoint biomarkers of response to chemopreventive strategies. In addition to having published more than 80 times, Dr. Massion has mentored more than 19 postdoctoral fellows, 100 graduate students, and 20 undergraduate students.

Drew Moghanaki, MD, MPH
Atlanta VA Medical Center
Chief, Radiation Oncology
Emory Winship Cancer Institute
Acting Associate Professor, Department of Radiation Oncology
Dr. Drew Moghanaki is Chief of the Radiation Oncology Department at the Atlanta Veterans Affairs Medical Center. He is also an acting associate professor at the Winship Cancer Institute at Emory University. He is a widely recognized leader in lung cancer research and directs several highly visible national projects in the VA. This includes the VA Partnership to Increase Access to Lung Screening (VA-PALS) and the phase III randomized VA Lung Cancer Surgery or Stereotactic Radiotherapy. He is a member, advisor, and chair of multiple committees for national organizations that include the American Cancer Society, American Society of Radiation Oncology, the GO2 Foundation for Lung Cancer, and LUNGevity Foundation.
Paul K. Paik, MD
Memorial Sloan Kettering Cancer Center
Associate Attending Physician
Clinical Director, Thoracic Oncology Service
Dr. Paik specializes in the treatment of lung cancers. His research focuses on squamous cell lung cancer therapy, targeted therapeutics, and translational therapies aimed at the metastatic process.

Lawrence H. Schwartz, MD
Columbia University Medical Center:
James Picker Professor and Chairman, Department of Radiology
NewYork-Presbyterian/Columbia University Medical Center:
Radiologist-in-Chief
Dr. Schwartz is internationally recognized for the innovative application of new technology in imaging to improve both clinical care and drug discovery. Renowned in the field of oncologic imaging, he is an authority on the development and validation of imaging biomarkers. His research has focused on new computational and functional techniques that utilize physiologic imaging and advanced image processing to assess and correlate imaging characteristics with molecular features of disease processes, in particular solid tumors of the chest, abdomen, and pelvis. At Memorial Sloan Kettering Cancer Center, Dr. Schwartz founded the Laboratory for Computational Image Analysis, which focuses on advanced image processing to quantitatively assess therapeutic efficacy in clinical care and drug discovery.

LeCia V. Sequist, MD, MPH
Harvard Medical School:
The Landry Family Associate Professor of Medicine
Massachusetts General Hospital Cancer Center
Dr. Sequist is originally from Michigan and studied chemistry at Cornell University. She received her MD from Harvard Medical School and trained in internal medicine at the Brigham and Women’s Hospital and in hematology/oncology at the Dana-Farber Cancer Institute, where she also received an MPH from the Harvard School of Public Health. She joined the faculty at the Massachusetts General Hospital Cancer Center in 2005 and has an active clinical and translational research career, as well as a busy practice caring for patients with lung cancer. She is currently the Landry Family Associate Professor of Medicine at Harvard Medical School and the Director of the Center for Innovation in Early Cancer Detection at Massachusetts General Hospital. She has held grants from the NIH, the DOD, and many private foundations. Dr. Sequist’s research focuses on studying targeted therapeutics for lung cancer and bringing new non-invasive tests like circulating tumor cells and circulating tumor DNA to treat and detect lung cancer. In her free time, she likes to spend time with her husband, two sons and her dog, and is a hockey and dance mom.

Alice T. Shaw, MD, PhD
Novartis Institutes for BioMedical Research
Vice President, Global Head of Translational Clinical Oncology
Dr. Shaw is the vice president, global head of Translational Clinical Oncology, at Novartis Institutes for BioMedical Research. Prior to that, she was director of the Center for Thoracic Cancers at Massachusetts General Hospital. She was also professor of medicine at Harvard Medical School. Her clinical research focuses on subsets of NSCLC that have unique driver mutations, such as EGFR, ALK, and ROS1. Her translational research focuses on understanding and making clear the mechanisms of resistance to targeted therapies; she is currently developing novel combination treatment strategies. Dr. Shaw’s
research has helped to develop numerous FDA-approved targeted therapies for patients with oncogene-driven NSCLC, such as crizotinib (Xalkori®) for patients with ALK or ROS1 rearrangements, and ceritinib (Zykadia®) and alectinib (Alecensa®) for patients with crizotinib-resistant, ALK-rearranged NSCLC.

**Steven J. Skates, PhD**  
*Harvard Medical School and Massachusetts General Hospital*  
*Associate Professor*

Dr. Skates developed the Risk of Ovarian Cancer Algorithm (ROCA) along with Robert C. Knapp, MD, professor emeritus, Harvard Medical School. Dr. Skates and his colleagues applied the algorithm to blood samples in an ovarian cancer screening study conducted by Ian Jacobs, MD, of St. Bartholomew's Hospital, London. Dr. Skates received his Bachelor of Science degree in Mathematics at the University of Western Australia, Perth, Australia. He completed his PhD in Biostatistics at the University of Chicago in 1987.

**Avrum E. Spira, MD, MSci**  
*Global Head, Lung Cancer Initiative, Johnson & Johnson*  
*Professor of Medicine, Pathology & Bioinformatics, Boston University School of Medicine*  
*Director, J&J Innovation Lung Cancer Center at Boston University*  
*Alexander Graham Bell Professor in Healthcare Entrepreneurship, Boston University*

Dr. Spira’s laboratory research interests focus on applying high-throughput genomic and bioinformatics tools to the translational study of lung cancer and Chronic Obstructive Lung Disease (COPD). The primary research focus of the lab is to determine how cigarette smoking affects cell gene expression and to use this information to develop a biomarker for lung cancer that can identify that subset of smokers who have, or are at risk for developing, lung cancer.

**Anil Vachani, MD, MS**  
*Perelman School of Medicine, University of Pennsylvania*  
*Associate Professor of Medicine*  
*Pulmonary, Allergy, and Critical Care Division*

Dr. Vachani’s research is focused on the discovery and validation of early detection and treatment prediction biomarkers for lung cancer and mesothelioma. Additional areas of research include studies on the measurement of biomarkers from circulating tumor cells and circulating free DNA. Finally, he is conducting studies on population level uptake of genomic and genetic technologies for treatment decisions in lung cancer using cancer registry and claims data.